-
Je něco špatně v tomto záznamu ?
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)
J. Čelutkienė, R. Pudil, T. López-Fernández, J. Grapsa, P. Nihoyannopoulos, J. Bergler-Klein, A. Cohen-Solal, D. Farmakis, CG. Tocchetti, S. von Haehling, V. Barberis, FA. Flachskampf, I. Čeponienė, E. Haegler-Laube, T. Suter, T. Lapinskas, S....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Medline Complete (EBSCOhost)
od 2000-03-01 do Před 1 rokem
Wiley Free Content
od 1999 do Před 1 rokem
PubMed
32621569
DOI
10.1002/ejhf.1957
Knihovny.cz E-zdroje
- MeSH
- antitumorózní látky škodlivé účinky MeSH
- kardiologie * MeSH
- lidé MeSH
- nádory * farmakoterapie MeSH
- srdeční selhání * MeSH
- vaskulární endoteliální růstový faktor A MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position statement examines the role of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging and computed tomography in the management of cancer patients. The Imaging and Cardio-Oncology Study Groups of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the ESC have evaluated the current evidence for the value of modern CV imaging in the cardio-oncology field. The most relevant echocardiographic parameters, including global longitudinal strain and three-dimensional ejection fraction, are proposed. The protocol for baseline pre-treatment evaluation and specific surveillance algorithms or pathways for anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor tyrosine kinase inhibitors, BCr-Abl tyrosine kinase inhibitors, proteasome inhibitors and immune checkpoint inhibitors are presented. The indications for CV imaging after completion of oncology treatment are considered. The typical consequences of radiation therapy and the possibility of their identification in the long term are also summarized. Special populations are discussed including female survivors planning pregnancy, patients with carcinoid disease, patients with cardiac tumours and patients with right heart failure. Future directions and ongoing CV imaging research in cardio-oncology are discussed.
1 M Sechenov's 1st Moscow State Medical University of Ministry of Health Moscow Russia
American Medical Center American Heart Institute Nicosia Cyprus
Baker Heart and Diabetes Institute Melbourne Australia
Berlin Institute of Health Center for Regenerative Therapies
Cardio Oncology Service Royal Brompton Hospital London UK
Cardiologist in Practice Turin Italy
Cardiology Clinical Academic Group St George's Hospitals NHS Trust University of London London UK
Cardiology Department La Paz University Hospital IdiPAz Ciber CV Madrid Spain
Cardiology Department University Hospital Ramón y Cajal Madrid Spain
CIBERCV Instituto de Salud Carlos 3 Madrid Spain
Department of Advanced Biomedical Sciences Federico 2 University Hospital Naples Italy
Department of Cardiac Magnetic Resonance Royal Brompton Hospital London UK
Department of Cardiology and Pneumology University of Göttingen Medical Centre Göttingen Germany
Department of Cardiology Charité Campus Benjamin Franklin Berlin Germany
Department of Cardiology CHVZ Laboratory Universitair Ziekenhuis Brussel Brussels Belgium
Department of Cardiology Inselspital University of Bern Bern Switzerland
Department of Cardiology Leiden University Medical Centre Leiden The Netherlands
Department of Cardiology Medical Academy Lithuanian University of Health Sciences Kaunas Lithuania
Department of Cardiology Medical University of Vienna Vienna Austria
Department of Cardiology Oslo University Hospital Rikshospitalet Oslo Norway
Department of Cardiology St Bartholomew Hospital Barts Health Trust London UK
Department of Health Medicine and Caring Sciences Linköping University Linköping Sweden
Department of Medical Sciences IRCCS San Raffaele Pisana Rome Italy
Department of Nuclear Medicine Royal Brompton Hospital London UK
Division of Cardiology and Metabolism Department of Cardiology Charité
DZHK partner site Berlin Berlin Germany
Emergency Institute for Cardiovascular Diseases C C Iliescu Bucuresti Romania
Faculty of Medicine University of Oslo Oslo Norway
Heart Clinic Hirslanden Hirslanden Hospital Zurich Switzerland
Heart Failure Unit Cardiology Guglielmo da Saliceto Hospital Piacenza Italy
IRCCS San Raffaele Pisana Rome Italy
National Heart and Lung Institute Imperial College London Hammersmith Hospital London UK
National Heart and Lung Institute Imperial College London UK
Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel
State Research Institute Centre For Innovative Medicine Vilnius Lithuania
Tel Aviv Jaffa District Clalit Health Services Tel Aviv Israel
UMR S 942 Cardiology Department Hôpital Lariboisière AP HP Université de Paris Paris France
Université de Paris CIC1418 Paris Cardiovascular Research Center INSERM Paris France
University Alcala Madrid Spain
University Heart Center Department of Cardiology University Hospital Zurich Zurich Switzerland
University of Belgrade Faculty of Medicine and Serbian Academy of Sciences and Arts Belgrade Serbia
University of Cyprus Medical School Nicosia Cyprus
University of Medicine Carol Davila Bucuresti Romania
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020174
- 003
- CZ-PrNML
- 005
- 20230131100329.0
- 007
- ta
- 008
- 210728s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ejhf.1957 $2 doi
- 035 __
- $a (PubMed)32621569
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Čelutkienė, Jelena $u Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania $u State Research Institute Centre For Innovative Medicine, Vilnius, Lithuania
- 245 10
- $a Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC) / $c J. Čelutkienė, R. Pudil, T. López-Fernández, J. Grapsa, P. Nihoyannopoulos, J. Bergler-Klein, A. Cohen-Solal, D. Farmakis, CG. Tocchetti, S. von Haehling, V. Barberis, FA. Flachskampf, I. Čeponienė, E. Haegler-Laube, T. Suter, T. Lapinskas, S. Prasad, RA. de Boer, K. Wechalekar, MS. Anker, Z. Iakobishvili, C. Bucciarelli-Ducci, J. Schulz-Menger, B. Cosyns, O. Gaemperli, Y. Belenkov, JS. Hulot, M. Galderisi, P. Lancellotti, J. Bax, TH. Marwick, O. Chioncel, T. Jaarsma, W. Mullens, M. Piepoli, T. Thum, S. Heymans, C. Mueller, B. Moura, F. Ruschitzka, JL. Zamorano, G. Rosano, AJS. Coats, R. Asteggiano, P. Seferovic, T. Edvardsen, AR. Lyon
- 520 9_
- $a Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position statement examines the role of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging and computed tomography in the management of cancer patients. The Imaging and Cardio-Oncology Study Groups of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the ESC have evaluated the current evidence for the value of modern CV imaging in the cardio-oncology field. The most relevant echocardiographic parameters, including global longitudinal strain and three-dimensional ejection fraction, are proposed. The protocol for baseline pre-treatment evaluation and specific surveillance algorithms or pathways for anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor tyrosine kinase inhibitors, BCr-Abl tyrosine kinase inhibitors, proteasome inhibitors and immune checkpoint inhibitors are presented. The indications for CV imaging after completion of oncology treatment are considered. The typical consequences of radiation therapy and the possibility of their identification in the long term are also summarized. Special populations are discussed including female survivors planning pregnancy, patients with carcinoid disease, patients with cardiac tumours and patients with right heart failure. Future directions and ongoing CV imaging research in cardio-oncology are discussed.
- 650 _2
- $a antitumorózní látky $x škodlivé účinky $7 D000970
- 650 12
- $a kardiologie $7 D002309
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a srdeční selhání $7 D006333
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory $x farmakoterapie $7 D009369
- 650 _2
- $a vaskulární endoteliální růstový faktor A $7 D042461
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pudil, Radek $u First Department of Medicine - Cardioangiology, Charles University Prague, Medical Faculty and University Hospital Hradec Králové, Hradec Kralove, Czech Republic
- 700 1_
- $a López-Fernández, Teresa $u Cardiology Department, La Paz University Hospital, IdiPAz, Ciber CV, Madrid, Spain
- 700 1_
- $a Grapsa, Julia $u Department of Cardiology, St Bartholomew Hospital, Barts Health Trust, London, UK
- 700 1_
- $a Nihoyannopoulos, Petros $u Unit of Inherited Cardiovascular Diseases/Heart Center of the Young and Athletes, First Department of Cardiology, Hippokrateion General Hospital, National and Kapodistrian University of Athens, Athens, Greece $u National Heart and Lung Institute Imperial College London, Hammersmith Hospital, London, UK
- 700 1_
- $a Bergler-Klein, Jutta $u Department of Cardiology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Cohen-Solal, Alain $u UMR-S 942, Cardiology Department, Hôpital Lariboisière, AP-HP, Université de Paris, Paris, France
- 700 1_
- $a Farmakis, Dimitrios $u University of Cyprus Medical School, Nicosia, Cyprus $u Cardio-Oncology Clinic, Heart Failure Unit, Department of Cardiology, Athens University Hospital Attikon, National and Kapodistrian University of Athens, Athens, Greece $7 xx0281405
- 700 1_
- $a Tocchetti, Carlo Gabriele $u Department of Translational Medical Sciences, and Interdepartmental Center for Clinical and Translational Research (CIRCET), Federico II University, Naples, Italy
- 700 1_
- $a von Haehling, Stephan $u Department of Cardiology and Pneumology, University of Göttingen Medical Centre, Göttingen, Germany
- 700 1_
- $a Barberis, Vassilis $u American Medical Center, American Heart Institute, Nicosia, Cyprus
- 700 1_
- $a Flachskampf, Frank A $u Department of Medical Sciences, Uppsala University, Clinical Physiology and Cardiology, Akademiska Hospital, Uppsala, Sweden
- 700 1_
- $a Čeponienė, Indrė $u Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
- 700 1_
- $a Haegler-Laube, Eva $u Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland
- 700 1_
- $a Suter, Thomas $u Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland
- 700 1_
- $a Lapinskas, Tomas $u Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
- 700 1_
- $a Prasad, Sanjay $u Department of Cardiac Magnetic Resonance, Royal Brompton Hospital, London, UK $u National Heart and Lung Institute, Imperial College, London, UK
- 700 1_
- $a de Boer, Rudolf A $u Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- 700 1_
- $a Wechalekar, Kshama $u Department of Nuclear Medicine, Royal Brompton Hospital, London, UK
- 700 1_
- $a Anker, Markus S $u Division of Cardiology and Metabolism, Department of Cardiology, Charité; and Berlin Institute of Health Center for Regenerative Therapies (BCRT); and DZHK (German Centre for Cardiovascular Research), partner site Berlin; and Department of Cardiology, Charité Campus Benjamin Franklin, Berlin, Germany
- 700 1_
- $a Iakobishvili, Zaza $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel $u Tel Aviv-Jaffa District, Clalit Health Services, Tel Aviv, Israel
- 700 1_
- $a Bucciarelli-Ducci, Chiara $u Bristol Heart Institute, Bristol NIHR Biomedical Research Centre and Clinical Research and Imaging Centre (CRIC) Bristol, University Hospitals Bristol NHS Trust and University of Bristol, Bristol, UK
- 700 1_
- $a Schulz-Menger, Jeanette $u Working Group on Cardiovascular Magnetic Resonance, Experimental and Clinical Research Center a joint cooperation between the Charité - Universitätsmedizin Berlin, Department of Internal Medicine and Cardiology and the Max-Delbrueck Center for Molecular Medicine, and HELIOS Klinikum Berlin Buch, Department of Cardiology and Nephrology, Berlin, Germany $u DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
- 700 1_
- $a Cosyns, Bernard $u Department of Cardiology, CHVZ (Centrum voor Hart en Vaatziekten), ICMI (In Vivo Cellular and Molecular Imaging) Laboratory, Universitair Ziekenhuis Brussel, Brussels, Belgium
- 700 1_
- $a Gaemperli, Oliver $u Heart Clinic Hirslanden, Hirslanden Hospital, Zurich, Switzerland
- 700 1_
- $a Belenkov, Yury $u I.M. Sechenov's First Moscow State Medical University of Ministry of Health (Sechenov University), Moscow, Russia
- 700 1_
- $a Hulot, Jean-Sébastien $u Université de Paris, CIC1418, Paris Cardiovascular Research Center, INSERM, Paris, France
- 700 1_
- $a Galderisi, Maurizio $u Department of Advanced Biomedical Sciences, Federico II University Hospital, Naples, Italy
- 700 1_
- $a Lancellotti, Patrizio $u University of Liège Hospital, GIGA Cardiovascular Sciences, Department of Cardiology, CHU SartTilman, Liège, Belgium
- 700 1_
- $a Bax, Jeroen $u Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands
- 700 1_
- $a Marwick, Thomas H $u Baker Heart and Diabetes Institute, Melbourne, Australia
- 700 1_
- $a Chioncel, Ovidiu $u Emergency Institute for Cardiovascular Diseases C.C. Iliescu, Bucuresti, Romania $u University of Medicine Carol Davila, Bucuresti, Romania
- 700 1_
- $a Jaarsma, Tiny $u Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden $u Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands
- 700 1_
- $a Mullens, Wilfried $u Ziekenhuis Oost Limburg, University Hasselt, Genk, Belgium
- 700 1_
- $a Piepoli, Massimo $u Heart Failure Unit, Cardiology, Guglielmo da Saliceto Hospital, Piacenza, Italy $u University of Parma, Parma, Italy
- 700 1_
- $a Thum, Thomas $u Hannover Medical School, Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover, Germany
- 700 1_
- $a Heymans, Stephane $u Department of Cardiology, CARIM School for Cardiovascular Diseases Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands $u William Harvey Research Institute, Barts Heart Centre, Queen Mary University of London, Charterhouse Square, London, UK $u Department of Cardiovascular Sciences, Centre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium
- 700 1_
- $a Mueller, Christian $u Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland
- 700 1_
- $a Moura, Brenda $u Cardiology Department, Military Hospital, and CINTESIS, CardioCare, Faculty of Medicine, Porto University, Porto, Portugal
- 700 1_
- $a Ruschitzka, Frank $u University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
- 700 1_
- $a Zamorano, Jose Luis $u Cardiology Department, University Hospital Ramón y Cajal, Madrid, Spain $u University Alcala, Madrid, Spain $u CIBERCV, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- 700 1_
- $a Rosano, Giuseppe $u Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy $u Cardiology Clinical Academic Group, St George's Hospitals NHS Trust University of London, London, UK
- 700 1_
- $a Coats, Andrew J S $u IRCCS San Raffaele Pisana, Rome, Italy
- 700 1_
- $a Asteggiano, Riccardo $u Cardiologist in Practice, Turin, Italy
- 700 1_
- $a Seferovic, Petar $u University of Belgrade Faculty of Medicine and Serbian Academy of Sciences and Arts, Belgrade, Serbia
- 700 1_
- $a Edvardsen, Thor $u Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway $u Faculty of Medicine, University of Oslo, Oslo, Norway
- 700 1_
- $a Lyon, Alexander R $u National Heart and Lung Institute, Imperial College, London, UK $u Cardio-Oncology Service, Royal Brompton Hospital, London, UK
- 773 0_
- $w MED00006634 $t European journal of heart failure $x 1879-0844 $g Roč. 22, č. 9 (2020), s. 1504-1524
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32621569 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20230131100326 $b ABA008
- 999 __
- $a ok $b bmc $g 1690877 $s 1140620
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 22 $c 9 $d 1504-1524 $e 20200821 $i 1879-0844 $m European journal of heart failure $n Eur J Heart Fail $x MED00006634
- LZP __
- $a Pubmed-20210728
